Recent News

• 12.10.2024 - Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
• 11.05.2024 - Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
• 11.04.2024 - Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
• 10.30.2024 - Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

Recent Filings

• 01.30.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 01.23.2025 - EFFECT Notice of Effectiveness
• 01.15.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 01.15.2025 - F-3 Registration statement by foreign private issuers
• 12.10.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.10.2024 - EX-99.1 EX-99.1